RecruitingPhase 2NCT06318286

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

Studying Pleural mesothelioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hyogo Medical University
Principal Investigator
Kozo Kuribayashi, MD, PhD
Department of Respiratory Medicine and Hematology, Hyogo Medical University Hospital
Intervention
Lenvatinib(drug)
Enrollment
25 target
Eligibility
18 years · All sexes
Timeline
20242026

Study locations (1)

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06318286 on ClinicalTrials.gov

Other trials for Pleural mesothelioma

Additional recruiting or active studies for the same condition.

See all trials for Pleural mesothelioma

← Back to all trials